High-Content Analysis: Technologies, Applications, Market Analysis
By James Kling and Richard Fisler
SURVEY QUESTIONS
1. Please describe your organization.
2. Please describe your position within your organization.
3. In what category does your high-content analysis research fall?
4. To which of the following fields do you apply high-content analysis? Apoptosis, cell cycle inhibitors, cell viability, GPCRs, ion channels, receptor studies, kinases, receptor internalization and trafficking, signal protein analyses, toxicity assays, other
5. What types of high-content analysis assays do you run?
6. Which of the following HCA applications do you regularly carry out? Changes in morphology and the cytoskeleton, cellular differentiation, cell-cell interactions and adhesion, chemotaxis and motility, spatial distribution changes, molecular biosensors, other
7. Does your organization conduct any of the following activities? 3-D cellular cluster analysis, colocalization studies, mitochondrial morphology/health, receptor internalization – pits, cytoskeletal analysis, receptor internalization – vesicles, transfluor GPCR activation assay
8. What technical or economic barriers do you see to the overall adoption of high-content analysis, that is, what limits purchase of additional instruments?
9. How do you regard high-content analysis's importance to your overall drug discovery and development effort?
10. What percentage of high-throughput screening experiments do you perform using HCA instrumentation?
11. What percentage of your high-content analysis assays employ confocal instruments?
12. What percentage of your HCA assays are kinetic/live cell assays?
13. What do you project the percentage of kinetic/live cell assays to be in 2 years?
14. What technical advances would you most welcome in next-generation HCA systems?
15. Do you use software shipped with your HCA instrument or do you use third-party software?
16. Do you anticipate purchasing third-party software in the next 12 months?
17. What do you consider the primary weakness of HCA software?
18. How many HCA instruments does your organization currently operate?
19. Is your HCA group a part of the high-throughput screening group or is it a separate department?
20. Where in your organization is the HCA instrumentation located?